Walvax Biotechnology Co., Ltd. (SHE:300142)
China · Delayed Price · Currency is CNY 12.55
+0.14 (1.13%)
Sep 8, 2025, 3:04 PM CST
Walvax Biotechnology Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | 14.76 | 142.16 | 419.39 | 728.65 | 427.75 | 1,003 | Upgrade |
Depreciation & Amortization | 398.57 | 388.54 | 317.23 | 264.93 | 143.84 | 123.95 | Upgrade |
Other Amortization | 22.93 | 23.02 | 16.1 | 10.57 | 5.71 | 4.46 | Upgrade |
Loss (Gain) From Sale of Assets | 1.53 | 1.77 | 0.83 | 0.38 | -0.23 | 1.08 | Upgrade |
Asset Writedown & Restructuring Costs | 87.11 | 7.68 | 11.31 | 1.66 | 5.11 | 2.41 | Upgrade |
Loss (Gain) From Sale of Investments | -17.98 | 93.31 | 227.64 | 187.54 | 222.86 | -285.29 | Upgrade |
Provision & Write-off of Bad Debts | 102.56 | 64.14 | 39.72 | -1.28 | -4.95 | -7.29 | Upgrade |
Other Operating Activities | 24.71 | 110.72 | 295.46 | 324.44 | 154.22 | 180.33 | Upgrade |
Change in Accounts Receivable | 655.72 | 781.3 | 535.7 | -1,241 | -614.65 | -1,495 | Upgrade |
Change in Inventory | 171.75 | 115.88 | -134.9 | -178.79 | -390.03 | -170.51 | Upgrade |
Change in Accounts Payable | -382.79 | -686.19 | -593.87 | 1,075 | 762.2 | 755.66 | Upgrade |
Operating Cash Flow | 1,063 | 1,037 | 1,134 | 1,201 | 705.28 | 114.19 | Upgrade |
Operating Cash Flow Growth | 26.70% | -8.58% | -5.64% | 70.36% | 517.62% | 84.13% | Upgrade |
Capital Expenditures | -386.53 | -550.03 | -945.52 | -1,091 | -1,103 | -407.13 | Upgrade |
Sale of Property, Plant & Equipment | 0.61 | 0.47 | 0.74 | 0.34 | 3.73 | 4.47 | Upgrade |
Divestitures | - | - | 140 | 149.39 | 75.68 | 75 | Upgrade |
Investment in Securities | 10 | -722 | -10 | - | 41.18 | -407.56 | Upgrade |
Other Investing Activities | 4.9 | 4.9 | 6.78 | 6.26 | 5.74 | 5.22 | Upgrade |
Investing Cash Flow | -371.02 | -1,267 | -807.99 | -935.19 | -977.15 | -730 | Upgrade |
Short-Term Debt Issued | - | - | 96.51 | - | - | 40 | Upgrade |
Long-Term Debt Issued | - | 38.22 | 499.31 | 393.82 | 410 | - | Upgrade |
Total Debt Issued | - | 38.22 | 595.83 | 393.82 | 410 | 40 | Upgrade |
Short-Term Debt Repaid | - | -4.6 | -189.19 | - | - | - | Upgrade |
Long-Term Debt Repaid | - | -353.68 | -78.61 | -405.35 | -149.73 | - | Upgrade |
Total Debt Repaid | -288.73 | -358.28 | -267.8 | -405.35 | -149.73 | - | Upgrade |
Net Debt Issued (Repaid) | -288.73 | -320.07 | 328.03 | -11.54 | 260.27 | 40 | Upgrade |
Issuance of Common Stock | 0.18 | 0.18 | 36.18 | 397.11 | 1,221 | 150.21 | Upgrade |
Repurchase of Common Stock | - | - | -72.21 | -286.42 | - | - | Upgrade |
Common Dividends Paid | -44.35 | -40.94 | -19.98 | -50.11 | -83.31 | -31.73 | Upgrade |
Other Financing Activities | -1,156 | -10.21 | -35.37 | 45.77 | 338.48 | 56.6 | Upgrade |
Financing Cash Flow | -1,489 | -371.03 | 236.64 | 94.82 | 1,736 | 215.08 | Upgrade |
Foreign Exchange Rate Adjustments | 5.81 | 5.41 | 2.27 | 4.07 | -0.12 | -1 | Upgrade |
Net Cash Flow | -791.54 | -595.76 | 564.69 | 365.19 | 1,464 | -401.73 | Upgrade |
Free Cash Flow | 676.06 | 486.49 | 188.25 | 110.31 | -398.21 | -292.94 | Upgrade |
Free Cash Flow Growth | 1188.67% | 158.43% | 70.65% | - | - | - | Upgrade |
Free Cash Flow Margin | 26.59% | 17.24% | 4.58% | 2.17% | -11.50% | -9.97% | Upgrade |
Free Cash Flow Per Share | 0.42 | 0.30 | 0.12 | 0.07 | -0.25 | -0.19 | Upgrade |
Cash Income Tax Paid | 104.89 | 136.82 | 264.12 | 309.57 | 244.55 | 212.66 | Upgrade |
Levered Free Cash Flow | 312.34 | 406.85 | 74.57 | -495.85 | -257.05 | -1,023 | Upgrade |
Unlevered Free Cash Flow | 313.91 | 412.12 | 78.29 | -491.4 | -253.44 | -1,022 | Upgrade |
Change in Working Capital | 428.39 | 205.17 | -193.9 | -315.4 | -249.02 | -908.63 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.